Drug Price Trends for MEMANTINE-DONEPEZIL ER

Average Pharmacy Cost for MEMANTINE-DONEPEZIL ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
MEMANTINE-DONEPEZIL ER 14-10 MG	33342-0312-07	11.85793	EACH	2026-03-25
MEMANTINE-DONEPEZIL ER 28-10 MG	33342-0313-07	13.93861	EACH	2026-03-25
MEMANTINE-DONEPEZIL ER 14-10 MG	69680-0183-30	11.85793	EACH	2026-03-18

Market overview and price outlook for MEMANTINE-DONEPEZIL ER

Last updated: February 13, 2026

1. Market Status of MEMANTINE-DONEPEZIL ER

MEMANTINE-DONEPEZIL ER is a combination therapy indicated for moderate to severe Alzheimer’s disease. It merges two drugs: memantine, an NMDA receptor antagonist, and donepezil, a cholinesterase inhibitor. This fixed-dose formulation aims to improve cognitive symptoms by simultaneously targeting different pathways.

Currently, no FDA-approved fixed-dose combination (FDC) of memantine and donepezil exists. Developers have marketed separate formulations and co-administered therapies. Market entry depends on regulatory approvals for the fixed-dose version, which is under clinical development by several pharmaceutical companies.

2. Market Drivers

• Growing Alzheimer’s prevalence: As per WHO, over 55 million people exhibited dementia globally in 2020, with projections reaching 78 million by 2030.

• Unmet need: Patients with moderate to severe Alzheimer’s require combination therapies, with current options limited to separate drugs.

• Patent protections: Existing patents for branded memantine (Namenda) and donepezil (Aricept) restrict generic competition until mid-2020s, potentially delaying widespread adoption of FDCs.

3. Competitive Landscape

Drug/Treatment	Formulation	Marketed by	Status	Price Range (per month)
Memantine (Namenda)	Tablet, solution	Eisai/Merck	Marketed globally	$150–$250 (U.S.)
Donepezil (Aricept)	Tablet, disintegrating	Eisai/Pfizer	Marketed globally	$80–$200 (U.S.)
Memantine-Donepezil ER (FDC)	Extended-release capsule	Under development	Clinical trials ongoing	Not yet established

4. Price Projections

If approved, Memantine-Donepezil ER prices are expect to be approximately 20–40% higher than the combined cost of individual drugs due to convenience and potential efficacy benefits. Based on current market data:

• Estimated monthly price: $200–$350 in the U.S.

• Pricing comparison: The combined cost of separate memantine and donepezil ranges $230–$450, depending on formulations and dosage.

In markets outside the U.S., prices depend on local healthcare policies, patent status, and market competition.

5. Regulatory and Market Challenges

• Regulatory hurdles: The safety and efficacy data must support FDC approval. A delay in approval impacts pricing strategies and market penetration.

• Patent expiries: Pending generics can influence initial pricing, exerting downward pressure.

• Health insurance and reimbursement: Payor policies will determine the actual patient cost, influencing market uptake.

6. Sales Forecasts

Based on market adoption rates for similar drugs and current dementia treatment trends:

Year	Estimated global sales	Assumptions
2024	$50–$100 million	Launch expected in late 2023 or 2024, initial uptake moderate
2025–2027	$200–$500 million	Increased penetration, expanded indications, insurance coverage growth

Market penetration depends on regulatory approval timing and adoption by clinicians.

7. Key Factors Influencing Price and Market Entry

• Regulatory approval timelines: Approval delays push back revenue streams and price realization.

• Competition: Entry of generic monotherapies lowers overall cost, pressuring premium pricing of FDC.

• Market acceptance: Physicians may prefer co-prescription of separate drugs over FDC unless superior efficacy or convenience proven.

---

Key Takeaways

• No FDA-approved memantine-donepezil ER available presently; clinical-stage development is ongoing.

• Estimated initial U.S. price range: $200–$350 per month, likely higher than separate medications, due to added convenience.

• Long-term sales depend on regulatory approval, patent landscape, and physician acceptance.

• Market growth driven by rising Alzheimer’s cases, with sales forecasts reaching hundreds of millions USD over 3–5 years post-launch.

• Pricing strategies will be impacted by patent status, competitor dynamics, and reimbursement policies.

---

FAQs

Q1: When could Memantine-Donepezil ER realistically enter the market?
A1: Pending successful clinical trials, regulatory submission could occur in 2024, with approval potentially by 2025.

Q2: How does the pricing compare to existing Alzheimer’s therapies?
A2: It’s expected to be priced 20–40% higher than the combined cost of individual drugs, reflecting convenience and novel formulation benefits.

Q3: What factors could delay commercial success?
A3: Regulatory hurdles, safety concerns, patent disputes, or clinician reluctance to switch from established monotherapies.

Q4: Which competitors will influence its market share?
A4: Existing cholinesterase inhibitors, NMDA antagonists, and emerging combination therapies, especially generics.

Q5: How will healthcare policies affect its adoption?
A5: Reimbursement and formulary inclusion heavily influence prescribing and patient access; positive coverage promotes uptake.

---

References

[1] World Health Organization. Dementia Fact Sheet. 2020.
[2] IQVIA. The Global Use of Medicine in 2021.
[3] U.S. FDA Drug Approvals. 2023.
[4] MarketsandMarkets. Alzheimer’s Disease Therapeutics Market. 2022.